Astute Medical, Inc. will host an educational symposium bringing together an international panel of medical experts to discuss how newly validated biomarkers of acute kidney injury (AKI) risk can improve care of critically ill patients in the intensive care setting. The symposium, AKI Biomarkers of Risk Assessment: A New Age, will take place at the 31st International Vicenza Course on Critical Care Nephrology in Vicenza, Italy on Tuesday, June 11 from 15:00 to 16:30 local time.
Registration information for the symposium is available
at www.akiassessment.com.
Highlights of the event will be broadcast live via Twitter @ACuteKidneyMan.
“AKI incidence is rising and has recently been associated
with acute health events, chronic diseases as well as certain pharmaceutical
and recreational drug use,” says Dr. Claudio Ronco, director of the department
of nephrology at San Bartolo hospital in Vicenza, Italy. “If undetected and
unchecked, AKI can result in substantial kidney damage that can hinder quality
of life, raise the risk of readmission or even result in death.”
Dr. Ronco, who will moderate the symposium, is the author of a recent commentary on AKI published in Critical Care.
Presenters at the
symposium will discuss pathogenesis of AKI along with emerging management
strategies. Dr. John Kellum of the University of Pittsburgh Medical Center will
highlight the symposium with recent findings demonstrating the
use of two biomarkers found to be highly accurate in the assessment of AKI risk
and superior to current methods. Other featured speakers include Dr. Lakhmir
Chawla, associate professor of medicine at George Washington University, and
Dr. Max Bell, senior researcher and physician
in the Department of Anesthesiology, Surgical Services and Critical Care
Medicine at Karolinska University Hospital in Solna, Sweden.
Increasingly, hospital physicians worldwide are expressing concern about the health risk and cost burden of AKI.
“Kidney complications during hospitalization are as
frequent and dangerous to patients as heart attack,” says Dr. Kellum. “However,
unlike heart attack, AKI is silent, without signs and symptoms that guide risk
assessment. It is imperative that physicians remain abreast of emerging
techniques for risk assessment and management of this condition.”
Astute Medical, Inc. recently commenced European
commercialization of the NephroCheck® Test for AKI risk assessment. Astute Medical is an exhibitor at the 31st
International Vicenza Course on Critical Care Nephrology. Astute Medical’s booth is #17 located in the
main exhibit hall.
The NephroCheck® Test and the Astute140™ Meter are not available for sale in the United States.
Source: Astute Medical, Inc.
